Viewing Study NCT06900569


Ignite Creation Date: 2025-12-24 @ 10:50 PM
Ignite Modification Date: 2025-12-29 @ 7:54 AM
Study NCT ID: NCT06900569
Status: RECRUITING
Last Update Posted: 2025-04-20
First Post: 2025-03-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ashwagandha Supplementation for Prevention of Muscle Damage
Sponsor: University of Saskatchewan
Organization:

Study Overview

Official Title: Ashwagandha Supplementation for Recovery From Muscle-damaging Exercise and Sleep Quality
Status: RECRUITING
Status Verified Date: 2025-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Ashwagandha is an herbal supplement that has a wide range of benefits related to exercise when supplemented for about 8-12 weeks. This study aims to investigate whether short-term Ashwagandha supplementation can enhance muscle recovery following exercise by measuring muscle strength recovery, swelling, and soreness in the biceps.
Detailed Description: The purpose of the study is to determine the effects of Ashwagandha supplementation on recovery from muscle-damaging exercise. Ten to twenty participants will be randomized to receive Ashwagandha supplementation (600 mg/d) or placebo for 10 days. On day 7, participants will perform a muscle damaging exercise session (six sets of concentric and emphasized eccentric repetitions with the biceps). Before and after exercise and at 24, 48, and 72 hours after exercise, isometric muscle strength, muscle swelling (ultrasound), and muscle soreness will be assessed. The investigators hypothesize the Ashwagandha will alleviate symptoms of muscle damage (swelling and soreness) and enhance strength recovery after a bout of muscle-damaging exercise.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: